Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic (Part 1) and Safety and Tolerability of BI 1015550 on Top of Nintedanib and Pirfenidone (Part 2)

Trial Profile

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic (Part 1) and Safety and Tolerability of BI 1015550 on Top of Nintedanib and Pirfenidone (Part 2)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2018

At a glance

  • Drugs BI 1015550 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 20 Dec 2018 Planned End Date changed from 11 Jun 2019 to 23 Oct 2019.
    • 20 Dec 2018 Planned primary completion date changed from 4 Jun 2019 to 16 Oct 2019.
    • 01 Oct 2018 Planned End Date changed from 10 Dec 2018 to 11 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top